



GlaxoSmithKline Pharmaceuticals Limited
GSK House, Dr. Annie Besant Road,
Worli, Mumbai - 400 030
Tel No: +91 22 2495 9595
Fax No: +91 22 2495 9494
Web: www.gsk-india.com
Email: askus@gsk.com

17th May 2024

To,

BSE LIMITED

Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai - 400001

THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra-Kurla Complex, Bandra (East)
Mumbai - 400051

Dear Sirs,

Subject: Media release: Q4 & FY23-24

Please find enclosed a press release issued by the Company in respect of financial results for the quarter and year ended 31st March, 2024.

This is for your information and record.

Yours faithfully

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni
Vice President – Administration, Real Estate
& Company Secretary

CIN: L24239MH1924PLC001151



Press release

For media and investors only

Issued on: 17 May 2024

**GlaxoSmithKline Pharmaceutical Limited Reports Strong Double-Digit Growth
and improved profitability for the quarter**

Q 4 revenue growth at 16% and EBIDTA growth at 53%

**Board of Directors of the Company recommends a Dividend of Rs. 32 per equity share for the
12 months period ended March 31, 2024**

Mumbai, Maharashtra – GlaxoSmithKline (GSK) Pharmaceuticals Limited today declared financial results for the quarter ended March 31, 2024. Revenue for the quarter came in at Rs. 911 crores recorded a growth of 16%. Profit before exceptional items and tax for the quarter at Rs.266 crores recorded a growth of 51% with EBITDA margins at 28%.

The full year reported revenue was at Rs 3407 crores, a growth of 6%, demonstrating positive growth driven by a strong volume recovery thereby offsetting NLEM (National List of Essential Medicines) impact. Profit before exceptional items and tax for the year at Rs. 953 crores recorded a growth of 14% with EBITDA at 26.4% up by 150 bps.

Commenting on the results for Q4 and FY 2023-24, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, *“For Q4, we delivered a strong double-digit growth and a robust performance across our General Medicines, Specialty and Vaccines portfolio. Our General Medicines portfolio recorded strong double-digit growth of 12% for the quarter, driven by key focus brands Augmentin, Ceftum and Calpol. Despite the NLEM impact in previous quarters, all promoted brands outpaced their respective categories in growth and gained market share.*

Specialty portfolio led by Nucala and Trelegy has accelerated the momentum with highest patient recruitment in Q4.

For the vaccines business, over the last two quarters, we have seen a steady upswing in both adult and paediatric segments. This business delivered a Q4 growth of 35%. We continue to build on the momentum generated with the launch of Shingrix (Zoster Vaccine Recombinant, Adjuvanted) as we drive expansion of the Adult Immunisation category in India with innovative go-to-market (GTM) strategies.



Press release

For media and investors only

We also remain committed to accelerating digital transformation to drive focused reach, coverage and seamless omni-channel experience for our customers.”

GSK approaches its centennial milestone in India on November 12th, 2024, marking a remarkable century of commitment to enhancing and improving the quality of lives for millions in India. For 100 years, we have earned the trust of generations by consistently delivering high quality medicines and vaccines. This milestone not only honours our rich heritage but also underscores our unwavering dedication to serving the people of India through the decades.

About GlaxoSmithKline Pharmaceuticals Limited (GSK)

GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit GSK-India.com.

Media Contact

Ransom D' Souza - ransom.a.dsouza@gsk.com

Communications & Government Affairs